CN117062908A - 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用 - Google Patents

靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用 Download PDF

Info

Publication number
CN117062908A
CN117062908A CN202280009715.6A CN202280009715A CN117062908A CN 117062908 A CN117062908 A CN 117062908A CN 202280009715 A CN202280009715 A CN 202280009715A CN 117062908 A CN117062908 A CN 117062908A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antigen binding
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280009715.6A
Other languages
English (en)
Chinese (zh)
Inventor
安毛毛
邱熙然
陈思敏
郭诗雨
李博华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinyao Biology Shanghai Co ltd
Xingji Biology Suzhou Co ltd
Original Assignee
Xinyao Biology Shanghai Co ltd
Xingji Biology Suzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinyao Biology Shanghai Co ltd, Xingji Biology Suzhou Co ltd filed Critical Xinyao Biology Shanghai Co ltd
Publication of CN117062908A publication Critical patent/CN117062908A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202280009715.6A 2021-01-11 2022-01-11 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用 Pending CN117062908A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110033695 2021-01-11
CN2021100336953 2021-01-11
PCT/CN2022/071382 WO2022148480A1 (zh) 2021-01-11 2022-01-11 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用

Publications (1)

Publication Number Publication Date
CN117062908A true CN117062908A (zh) 2023-11-14

Family

ID=82357142

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280009715.6A Pending CN117062908A (zh) 2021-01-11 2022-01-11 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用

Country Status (7)

Country Link
US (1) US20240059764A1 (https=)
EP (1) EP4286409A4 (https=)
JP (1) JP2024503425A (https=)
KR (1) KR20230147616A (https=)
CN (1) CN117062908A (https=)
BR (1) BR112023013790A2 (https=)
WO (1) WO2022148480A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118480121A (zh) * 2024-05-13 2024-08-13 重庆原伦生物科技有限公司 一种特异性结合金黄色葡萄球菌蛋白a的抗体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410371A1 (en) * 2023-02-03 2024-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies against alpha-hemolysin from staphylococcus aureus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
WO2013093693A1 (en) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
TWI781130B (zh) * 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2020041394A1 (en) * 2018-08-23 2020-02-27 Trustees Of Tufts College Binding proteins, compositions and methods thereof for neutralization of infection of pathogens having a type iii secretion system
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
CN110577594B (zh) * 2019-08-19 2021-05-14 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a21、应用及试剂盒
CN110526967A (zh) * 2019-08-19 2019-12-03 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a13、应用及试剂盒
CN110526966B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b6、应用及试剂盒
CN110563839A (zh) * 2019-08-19 2019-12-13 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b1、应用及试剂盒
CN110526968B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b7、应用及试剂盒

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118480121A (zh) * 2024-05-13 2024-08-13 重庆原伦生物科技有限公司 一种特异性结合金黄色葡萄球菌蛋白a的抗体及其应用

Also Published As

Publication number Publication date
US20240059764A1 (en) 2024-02-22
KR20230147616A (ko) 2023-10-23
EP4286409A4 (en) 2025-01-01
EP4286409A1 (en) 2023-12-06
WO2022148480A1 (zh) 2022-07-14
JP2024503425A (ja) 2024-01-25
BR112023013790A2 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
KR20100021577A (ko) 에스.아우레우스 ＯＲＦ0657ｎ을 표적화하는 항원 결합 단백질
KR102058381B1 (ko) 인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법
CN112955548A (zh) 叶酸受体α特异性抗体
US20240067747A1 (en) Cd73-binding protein and use thereof
CN112094349A (zh) 靶向于白介素36r的抗体及其制备方法和应用
JP2024502091A (ja) Ｐｄ－１結合分子およびその使用
JP2023554326A (ja) Ｃｄ７３の抗原結合蛋白及びその使用
US20240059764A1 (en) ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF
CN114685666B (zh) 抗间皮素纳米抗体及其应用
CN117280034A (zh) 间皮素结合分子及其应用
CN115873114B (zh) Ctla-4结合分子及其应用
CN118591565A (zh) 抗tigit和pd-l1的双特异性抗原结合蛋白及其用途
CN114685667B (zh) 间皮素结合分子及其应用
CN115991784A (zh) 抗cd47-cldn18.2双特异性抗体及其用途
WO2022037528A1 (zh) 结合bcma的单可变结构域及抗原结合分子
CN113264999B (zh) 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
JP2007527703A (ja) 肺炎球菌表面付着因子Ａタンパク質（ＰｓａＡ）に関する結合メンバー
CN114957460A (zh) 交叉中和金黄色葡萄球菌毒素的抗原结合蛋白及其用途
EP4317182A1 (en) Antigen-binding protein targeting streptococcus pneumoniae hemolysin protein and use thereof
OA21956A (en) Antigen-binding protein targeting staphylococcus aureus α-toxin and application thereof.
CN117843793B (zh) 抗间皮素抗体、抗原结合片段及其用途
CN119350502A (zh) 靶向fap的抗原结合蛋白及其应用
OA21922A (en) Antigen-binding protein targeting streptococcus pneumoniae hemolysin protein and use thereof.
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination